FDA Panel Backs First Multi-Cancer Blood Test

A U.S. Food and Drug Administration advisory panel voted on Wednesday to recommend approval of Galleri, a blood test developed by biotech firm GRAIL that is designed to screen for signals from multiple cancer types from a single blood draw. If the agency follows the recommendation, Galleri would become the first FDA-approved multi-cancer early detection (MCED) test — a milestone in the effort to find cancers before symptoms appear.

The vote was decisive on safety and more cautious on the test’s broader value. The 10-member Molecular and Clinical Genetics Devices Panel voted unanimously, 10-0, that there is “reasonable assurance” Galleri is safe, but split 6-4 on whether there is reasonable assurance it is effective, and 7-2 with one abstention that its benefits outweigh its risks for adults aged 50 and older, according to STAT News. The FDA is not bound by the panel’s advice, though it typically follows it, and is expected to decide on GRAIL’s application “in the coming months.”

What the Test Does

Galleri is a blood-based “liquid biopsy” that detects cancer-specific DNA methylation patterns — chemical tags on tumor DNA shed into the bloodstream. GRAIL markets it as covering signals from more than 50 cancer types and says the test predicts the likely tissue of origin to guide follow-up diagnostics. Critically, it is intended for use in addition to, not as a replacement for, guideline-recommended screenings such as mammography and colonoscopy.

The test has been commercially available in the United States since 2021 as a laboratory-developed test, available by prescription and priced at $949. Most patients currently pay out of pocket, though FDA approval could open the door to insurance and Medicare coverage. Congress has already approved Medicare coverage for FDA-approved multi-cancer detection tests, with reimbursement allowed starting in 2028.

“The Galleri test was developed to improve the effectiveness and efficiency of our national cancer screening program by adding multi-cancer early detection to recommended screening,” GRAIL CEO Josh Ofman said in a company statement. “Today’s vote reinforces the strength of Galleri’s clinical evidence.”

The panel also recommended that Galleri’s marketing materials tell patients to continue routine cancer screenings and avoid characterizing the test as an “early” detection tool — a signal that regulators want it framed as an add-on with important limitations.

The Trial That Shadowed the Vote

The panel’s caution reflects the test’s most significant scientific complication: the landmark NHS-Galleri randomized controlled trial in England, whose results were presented in May 2026 at the American Society of Clinical Oncology annual meeting in Chicago.

That trial, reported by The Guardian, enrolled 142,942 people aged 50 to 77 with no cancer symptoms. Each participant had blood drawn annually for three years and received standard screening; half had their samples analyzed with Galleri. The trial failed its primary endpoint — it did not show a statistically significant reduction in late-stage (stage III-IV) cancer diagnoses when Galleri was added to standard screening. GRAIL highlighted secondary signals, notably a 14% reduction in stage IV cancers alone, but independent experts urged caution.

“The failure to meet the primary endpoint is the crux of the issue here,” said Prof Richard Houlston of the Institute of Cancer Research, London. “On the basis of results from this and smaller trials, there is no evidence base upon which to justify implementation of Galleri at a population scale.”

Dr Julie Gralow, ASCO’s chief medical officer, said the study showed “some encouraging trends toward tumour downstaging” but “did not statistically reduce late-stage cancers by its predefined primary endpoint.” Mortality data from the trial are expected in roughly two years.

Doctor and Expert Response

Ajay Goel, a professor at City of Hope, told Scientific American that the panel’s favorable vote “represents an important step forward for the field.” But Phil Castle, director of the National Cancer Institute’s Division of Cancer Prevention, warned the panel before the vote that “routine approval and broad population rollout would risk harm and waste resources” — pointing to the danger that a negative result could falsely reassure patients and delay proven screenings.

Michelle Tarver, who leads the FDA’s Center for Devices and Radiological Health, called blood-based multi-cancer detection a “genuinely promising opportunity,” a tone that captured the balance regulators are trying to strike.

The split vote itself is telling. Unanimity on safety, paired with a divided effectiveness vote, means the debate is no longer about whether the test is dangerous but whether the evidence is strong enough to justify widespread use.

What to Watch

Several key questions remain. First, and most immediately, will the FDA follow its panel and grant approval? GRAIL submitted its Premarket Approval application on January 29, 2026, after holding FDA Breakthrough Device designation since 2018.

Second, what will the trial’s mortality data show when they arrive in about two years? That outcome — whether Galleri actually saves lives, not merely shifts diagnoses — may ultimately matter more than any single vote.

Third, how will payers respond? Medicare reimbursement for approved multi-cancer detection tests could begin around 2028, but insurers will weigh the test’s $949 price against uncertain clinical utility.

For now, the vote marks a genuine first: a blood test for many cancers, from a single draw, has moved closer to the regulatory finish line than any of its predecessors. Whether it changes cancer outcomes at scale — or merely offers reassurance the evidence does not yet support — is a question the coming years will settle.